GABBR1 and cholangiocarcinoma: In addition, recent research has demonstrated that GABA-B receptor agonists have the ability to inhibit the proliferation of bile duct cancer cells via the GSK3α/β-STATA pathway and its downstream targets in cholangiocarcinoma from diabetic patients (86).